People · Operator
Named in public records as an officer, director or promoter · active 2011–2018 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Pediapharm Inc. | — | Pharmaceuticals | Series A | $7.7M | $237.6M | 2018 |
| Insys Therapeutics, Inc. | — | Biotechnology | Seed | $2.3M | $102.8M | 2011 |
Pierre Lapalme at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Pierre Lapalme on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Michael Mueller | 1 | 5 |
| Larry Dillaha | 1 | 3 |
| Benoit Gravel | 1 | 2 |
| Patrick Fourteau | 1 | 2 |
| Roland Boivin | 1 | 2 |
| Daniel Von Hoff | 1 | 2 |
| Normand Chartrand | 1 | 1 |
| Brian Tambi | 1 | 1 |
| Richard Mallery | 1 | 1 |
| Martin McCarthy | 1 | 1 |
| John Kapoor | 1 | 1 |
| Steven Meyer | 1 | 1 |
| Michael Babich | 1 | 1 |
| Sylvain Chretien | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.